Specialized probiotics in the prevention of obesity

Specialized probiotics in the prevention of obesity

Specialized probiotics that have a role in the prevention or treatment of conditions such as obesity, shown by a special study, from Hiroshima University. Conjugated linoleic acid (CLA) has been found to be associated with decreased body fat and inhibit the growth of colon cancer cells in humans and other animals. Certain type of gut bacteria can produce CLA. level of CLA in the mice's fat tissue quadrupled when they were fed this recombinant probiotic. Researchers conducted a study that rats supplemented with this recombinant probiotic had level of CLA quadrupled times higher than rats on a non-supplemented diet. If these findings are confirmed by further studies, which strongly suggest a role for using the probiotics-supplemented diet for the prevention of obesity. According to the researchers.

The study have been published in Microbiology.

What’s CLA 

CLA is a fatty acid that is produced in different versions by different bacteria. One type, called t10, c12 CLA, has been shown to be associated with decreased body fat in humans and other animals. t10, c12 CLA also has the ability to inhibit the growth of colon cancer cells and induce their death. However, this type of CLA is only produced by certain types of bacteria including Propionibacterium acnes -- a skin bacterium that can cause acne.

Resaerch content

In this study, an enzyme-encoding gene from P. acnes was transferred to the Lactobacillus strain allowing it to produce t10, c12 CLA. Lactobacillus strains are common inhabitants of the normal gut flora and are often found in probiotic products. The researchers found that the level of t10, c12 CLA in the mice's fat tissue quadrupled when they were fed this recombinant probiotic. Thus, this study demonstrates that gut microbes have an impact on host metabolism, and in particular fat composition.

Resaerch results

Dr Catherine Stanton, from Teagasc who led the study explained the significance of the results. "CLA has already been shown to alleviate non-alcoholic fatty liver disease that often accompanies obesity. Therefore, increasing levels of CLA in the liver by ingestion of a probiotic strain is of therapeutic relevance," she said. "Furthermore, fat is not an inert layer around our bodies, it is active and proinflammatory and is a risk factor for many diseases, including cancers. The work shows that there is potential to influence this through diet-microbe-host interactions in the gut."

The same group of researchers previously found that microbially produced CLA was able to reduce the viability of colon cancer cells by 92%. "It is possible that a CLA-producing probiotic may also be able to keep colon cancer cells in check. All our findings to date demonstrate that the metabolism of gut bacteria can modulate host cell activity in ways that are beneficial to the host," explained Dr Stanton. "We need to further investigate the effects of CLA-producing bacteria on human metabolism, but our work so far certainly opens up new possibilities for the use of probiotics for improvement of human health."

For relevant references, please use CNGBdb Literature database.

Source:Science Daily
Original title:Designer probiotics could reduce obesity
Reference link:https://www.sciencedaily.com/releases/2010/12/101222205346.htm